Business Wire

Fujitec Switches to Rimini Street for Oracle Database Support

Share

Rimini Street, Inc., (Nasdaq: RMNI), a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products, today announced that Fujitec Co., Ltd., a leading manufacturer of elevators and escalators, has switched to Rimini Street support for its Oracle Database software. By switching to Rimini Street, Fujitec immediately realized savings of 50 percent from what they had been paying Oracle for annual support fees, and they are also receiving Rimini Street’s more comprehensive, responsive support. Under Rimini Street support, Fujitec can continue to run its robust, stable Oracle Database 10.2 and 11.2 releases for a guaranteed minimum of 15 additional years without a required upgrade just to stay supported. Fujitec has also been able to free up vital resources from database maintenance that can be reinvested into important IT initiatives, including virtual reality and mobile applications, as well as an ongoing project to migrate systems to a new private cloud infrastructure.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171030006193/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Fujitec Switches to Rimini Street for Oracle Database Support (Photo: Business Wire)

Reduced IT Costs, Enhanced Productivity

In recent years, Fujitec’s strategy has been focused on reducing IT operating costs and delivering enhanced productivity. As part of this strategy, the company began migrating much of its IT infrastructure to a private cloud. Even with the migration to a more cost-effective private cloud infrastructure, the organization was incurring too high a cost for annual support fees and labor to maintain and operate its large scale, core database environment. These costs included a significant amount of effort devoted to self-support, primarily because Oracle was not providing the support services Fujitec needed. Oracle’s expensive annual fees, service deficiencies and excessive labor requirements led Fujitec to explore options that would reduce annual support costs, meet its support service needs as well as receive better quality support. Fujitec selected Rimini Street’s annual support to meet its objectives.

“When evaluating our overall IT budget, it was clear that Oracle’s annual maintenance and related costs for our Oracle Database landscape was a significant spend. When we evaluated Rimini Street support services, it became the obvious choice for us. We benefited from the immediate 50 percent reduction in our annual maintenance fees, labor savings from not having to perform release upgrades and additionally, we are now receiving more responsive and comprehensive support than what we had been receiving from Oracle,” said Kenji Tomooka, chief information officer, Information System Department, Fujitec Co. “With the cost savings realized by switching to Rimini Street, we have been able to fund other innovative IT projects. Our company has been successful migrating much of our IT infrastructure to the cloud and continuing our transformation toward a digital enterprise, while being able to keep applications we develop in-house on our core Oracle Database landscape.”

New Unparalleled Support

When evaluating their support and maintenance needs, Fujitec wanted the ability to work directly with expert engineers who could deliver more responsive service and a faster time to resolution. As with all Rimini Street clients, Fujitec now has an assigned senior level Primary Support Engineer (PSE) with at least 10 years’ experience with Oracle Database software, and is experiencing a superior service experience compared to the call-center support model they had experienced with Oracle annual support. Rimini Street PSE’s are available 24/7/365 to address any support issues, and all clients receive the Company’s industry-leading SLA guaranteeing a 15-minute response time for critical cases.

“Direct interaction with an assigned Rimini Street Primary Support Engineer appealed to us the most. Previously, we would submit a ticket with the vendor, and frequently there would be multiple support personnel involved, many junior level, and it was not clear who was responsible for providing the solution,” continued Tomooka. “With Rimini Street, all engineers, led by our Primary Support Engineer, work together until the problem is solved to our satisfaction. We did not have the sense of security with Oracle that comes from such a collaborative environment we have found with Rimini Street. Personally, this is my first experience to have partnered with a company where all employees are fully committed to moving our business forward, and I am impressed with the expert engineers who work the same way we do.”

“Japan CIOs are being tasked with examining organizational growth strategies, increasing efficiencies and cultivating digital transformation, all while reducing overall costs,” said Yorio Wakisaka, general manager, North East Asia, Rimini Street. “By switching its Oracle Database support to Rimini Street, Fujitec has been able to reinvest their savings into strategic IT innovation initiatives, including enabling them to leverage a private cloud infrastructure. With Rimini Street’s proven, award-winning support, Fujitec, and all of our clients, know their current core systems of record are supported for a guaranteed minimum of 15 additional years from the date they move to Rimini Street.”

About Rimini Street, Inc.

Rimini Street, Inc. (Nasdaq: RMNI) is a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products. The company has redefined enterprise software support services since 2005 with an innovative, award-winning program that enables licensees of IBM, Microsoft, Oracle, SAP and other enterprise software vendors to save up to 90 percent on total support costs. Clients can remain on their current software release without any required upgrades for a minimum of 15 years. Over 1,330 global Fortune 500, midmarket, public sector and other organizations from a broad range of industries currently rely on Rimini Street as their trusted, third-party support provider. To learn more, please visit http://www.riministreet.com, follow @riministreet on Twitter and find Rimini Street on Facebook and LinkedIn. (C-RMNI)

Forward-Looking Statements

Certain statements included in this communication are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “may,” “should,” “would,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “seem,” “seek,” “continue,” “future,” “will,” “expect,” “outlook” or other similar words, phrases or expressions. These forward-looking statements include, but are not limited to, statements regarding our industry, future events, as well as expected management, the estimated or anticipated future results and benefits of Rimini Street following the transaction, including the expected post-transaction ownership and cash and debt balances, future opportunities, estimates of Rimini Street’s total addressable market, and projections of customer savings. These statements are based on various assumptions and on the current expectations of management and are not predictions of actual performance, nor are these statements of historical facts. These statements are subject to a number of risks and uncertainties regarding Rimini Street’s business, and actual results may differ materially. These risks and uncertainties include, but are not limited to, changes in the business environment in which Rimini Street operates, including inflation and interest rates, and general financial, economic, regulatory and political conditions affecting the industry in which Rimini Street operates; adverse litigation developments; inability to refinance existing debt on favorable terms; changes in taxes, governmental laws, and regulations; competitive product and pricing activity; difficulties of managing growth profitably; the loss of one or more members of Rimini Street’s management team; failure to realize the anticipated benefits of the transaction, including difficulty in integrating the businesses of GPIAC and Rimini Street; uncertainty as to the long-term value of RMNI common stock; the inability to realize the expected amount and timing of cost savings and operating synergies; those discussed in GPIAC’s Annual Report on Form 10-K for the year ended December 31, 2016 under the heading “Risk Factors,” as updated from time to time by GPIAC’s and Rimini Street’s Quarterly Reports on Form 10-Q and other documents of GPIAC and Rimini Street on file with the Securities and Exchange Commission (“SEC”) or in the joint proxy statement/prospectus filed with the SEC by GPIAC. There may be additional risks that Rimini Street presently knows or that Rimini Street currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements provide Rimini Street’s expectations, plans or forecasts of future events and views as of the date of this communication. Rimini Street anticipates that subsequent events and developments will cause Rimini Street’s assessments to change. However, while Rimini Street may elect to update these forward-looking statements at some point in the future, Rimini Street specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Rimini Street's assessments as of any date subsequent to the date of this communication.

© 2017 Rimini Street, Inc. All rights reserved. “Rimini Street” is a registered trademark of Rimini Street, Inc. in the United States and other countries, and Rimini Street, the Rimini Street logo, and combinations thereof, and other marks marked by TM are trademarks of Rimini Street, Inc. All other trademarks remain the property of their respective owners, and unless otherwise specified, Rimini Street claims no affiliation, endorsement, or association with any such trademark holder or other companies referenced herein.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Rimini Street, Inc.
Michelle McGlocklin, +1-925-523-8414
mmcglocklin@riministreet.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Microba Announces Landmark GI Study Results From Over 4,600 Patients15.5.2025 05:12:00 EEST | Press release

Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”), a precision microbiome company, today announces preliminary results from the analysis of over 4,600 MetaXplore™ GI Plus test results, a comprehensive test for the assessment and management of lower gastrointestinal disorders, spanning symptoms including chronic pain, bloating, constipation, or diarrhea. This study demonstrates that MetaXplore can support clinicians to identify and address underlying gut issues that often go undetected by conventional testing. In over 70% of cases, the test revealed findings, such as abnormalities in gut bacteria, signs of infection, markers of inflammation or insufficiency that could inform targeted treatment strategies. Further, two-thirds of MetaXplore patients in a separate study of follow up survey results reported improvement of symptoms after their care was guided by the test results. This press release features multimedia. View the full release here: https://www.businesswire.

Bloomstreet Enters into Strategic Partnership Agreement with Google Israel for Market Expansion in Japan15.5.2025 05:00:00 EEST | Press release

Bloomstreet Inc. (Headquarters: Chuo-ku, Tokyo; President & CEO: Junichi Takayama; hereinafter “Bloomstreet”), a company that supports overseas enterprises entering the Japanese market, is pleased to announce a strategic partnership agreement with Google Israel Ltd. (Headquarters: Tel Aviv District; Country Manager: Barak Regev; hereinafter “Google Israel”). This partnership aims to support Israeli companies that operate globally with Google Ads and are seeking to expand into the Japanese market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250514387485/en/ How do Bloomstreet and Google Israel collaborate? The partnership between Bloomstreet and Google Israel is designed to support Israeli companies seeking to expand into the Japanese market by optimizing their website UI/UX, thereby enhancing the effectiveness of their Google Ads campaigns. Background of the Partnership Known as a "Start-up Nation," Israel is home to many

Rubedo Life Sciences’ Drug Discovery Platform, ALEMBIC™, Helps Identify Senescent or “Zombie” Neurons in New Study Linking Neuropathic Pain and Aging Published in Peer-Reviewed Scientific Journal Nature Neuroscience15.5.2025 04:11:00 EEST | Press release

Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that using open source codes integrated in the company’s broader propriety drug discovery platform, ALEMBIC™, helped to identify senescent neurons in a new study that found senescent neurons drive chronic pain with injury and age.1 Senescent cells, often called “zombie” cells, arise as the results of cellular stress and damage. These senescent cells do not die but undergo cellular changes, including secreting pro-inflammatory factors, thereby potentially contributing to inflammatory responses within the body.1 The study, led by Stanford University scientists, Vivianne Tawfik, MD, PhD, and Lauren Donovan, PhD, and co-authored by Rubedo team members, including Chief Scientific Officer Marco Quarta, PhD, and Chief Technology Officer Alex Laslavic, was published in the May 14th edition of Nat

The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 115.5.2025 00:03:00 EEST | Press release

Takeda (TSE: 4502/NYSE:TAK) today announced that the New England Journal of Medicine published data from the Phase 2b trial of oveporexton (TAK-861) in people with narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to restore orexin signaling to address the underlying orexin deficiency that causes NT1. Results demonstrated significant improvement in objective and subjective measures of excessive daytime sleepiness (EDS), reductions in cataplexy events and clinically meaningful improvements in disease severity and quality of life across all doses tested compared to placebo through eight weeks of treatment. NT1 is a severe, chronic neurological condition caused by a significant loss of orexin-producing neurons, resulting in low levels of orexin leading to EDS, cataplexy (sudden loss of muscle tone), cognitive symptoms, disrupted nighttime sleep, hallucinations that occur as one falls asleep or wakes up and sleep paralysis.T

BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation14.5.2025 23:05:00 EEST | Press release

BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will share data across a range of hematologic malignancies at the European Hematology Association (EHA) Congress in Milan, Italy, June 12–15. BeiGene has 31 abstracts accepted at EHA 2025, with four selected for oral presentations, featuring data from its best-in-class Bruton’s tyrosine kinase (BTK) inhibitor BRUKINSA® (zanubrutinib) and its investigational pipeline assets – a next-generation BCL2 inhibitor, sonrotoclax, and BTK protein degrader, BGB-16673. These data reflect BeiGene’s vision to redefine standards of care in hematology through next-generation science and patient-focused innovation. “With three cornerstone hematology assets – BRUKINSA, sonrotoclax and BGB-16673 – we are advancing a potentially best-in-class portfolio in B-cell malignancies,” said Lai Wang, Ph.D. Global Head of R&D. “At EHA 2025, we’ll share 31 accepted ab

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye